N60 — Benign Mammary Dysplasia: What This ICD-10 Code Means

If an ultrasound report, a mammogram or a discharge note carries the code N60, the first instinct is to search for how serious it is. The direct answer first: N60 is a benign code — the word benign is written into the official category name. Below we take the code apart, show where it appears, how it differs from neighbouring codes and what to do with the record.

What ICD-10 code N60 means, element by element

The official wording of N60 is «Benign mammary dysplasia». Element by element:

• N — the letter of ICD-10 Class XIV: «Diseases of the genitourinary system» (N00–N99). Breast disorders are historically placed in this class; that is a quirk of the classification, not a link to the kidneys or bladder.
• N60–N64 — the block «Disorders of breast», covering benign changes, inflammation and other conditions of the breast, but not tumours — those live in the neoplasm classes.
• N60 — the category «Benign mammary dysplasia». Here dysplasia does not mean pre-cancer: it refers to structural remodelling of the tissue — glandular overgrowth, fibrosis, cyst formation.
• The fourth character specifies the form: N60.0 solitary cyst, N60.1 diffuse cystic mastopathy, N60.2 fibroadenosis, N60.3 fibrosclerosis, N60.4 mammary duct ectasia, N60.8 other benign mammary dysplasias, N60.9 unspecified.

Put together, N60 records: «benign changes typical of fibrocystic breast disease were found in the breast tissue». The code carries no information about malignancy — a separate category exists for that.

Where you may have seen this code

N60 appears in both clinical and purely administrative documents:

A practical point: the code in the header is always poorer than the report text. It contains no measurements, no lesion structure, no BI-RADS category and no follow-up advice — and that is exactly where the substance lies.

Is N60 dangerous? What benign mammary dysplasia means

The honest answer: the condition is benign, but not meaningless — it deserves calm attention rather than alarm.

What can be stated firmly:

• N60 is not cancer and not a stage of cancer. Malignant breast tumours are coded separately as C50, a different category in a different class.
• Fibrocystic change is very common. Benign remodelling of breast tissue is found in a large share of women of reproductive age and largely reflects hormonal influence on the gland.
• Most forms coded as N60 do not turn into cancer. Risk is meaningfully raised only by specific histological variants such as atypical hyperplasia, which are established by biopsy rather than by imaging and are coded differently.

What should not be played down:

• Dense fibrocystic tissue is harder to read on imaging, so a new lesion is easier to miss. That is why regular follow-up is scheduled — not because the condition is dangerous, but because it reduces visibility.
• If the report states BI-RADS 3 or higher, the timing and scope of the next examination are set by your doctor and should not be postponed.
• If the radiologist cannot classify a finding as clearly benign or malignant, the code D48 — «neoplasm of uncertain or unknown behaviour» — may be used. That is a request for clarification, not a cancer diagnosis.

Signs that warrant an immediate visit rather than a scheduled one: a hard fixed lump, skin or nipple retraction, nipple discharge (especially bloody), a change in breast shape, enlarged axillary lymph nodes. How to tell ordinary changes from concerning ones is covered in a separate guide on breast cancer.

Neighbouring codes and how they differ

Breast conditions are spread across several ICD-10 classes, so neighbouring codes look similar yet mean fundamentally different things:

The key pair to understand is N60 versus D24: in N60 the tissue as a whole is altered, in D24 there is a defined benign nodule. Neither is malignant.

Which examinations are usually ordered for fibrocystic breast change

The workup is standard and almost always non-invasive:

• Breast ultrasound — the main method under 40 and in dense tissue; it separates cysts from solid nodules well.
• Mammography — the X-ray method of choice from around 40 and the basis of screening programmes.
• Clinical breast examination — palpation, symmetry, skin and nipple condition, axillary lymph nodes.
• BI-RADS category — a score from 1 to 5 in the report that decides between observation, further imaging and biopsy.
• Ultrasound-guided biopsy — only when the picture is suspicious; it is not part of every N60 pathway.
• Tumour markers — they neither confirm nor exclude the diagnosis; their limited role is explained in a separate review of the CA 15-3 marker.

The practical difficulty is that these reports are written in specialist language: «fibrocystic remodelling», «anechoic lesion with clear margins», «BI-RADS 2». Understanding what your own images actually describe helps far more than searching the code online.

What to do next

1. Read the report text, not just the code. Look for sizes, structure, margins and the BI-RADS category — they say far more than the line N60.
2. Ask your doctor about the follow-up interval. For benign change a repeat ultrasound or mammogram is usually scheduled; that interval is the most important sentence in your document.
3. Have your own study explained in plain language. Arriving at the appointment with questions rather than anxiety makes the visit far more useful.
4. Know the signs that cannot wait. They are listed above and described in detail in the guide on breast cancer.
5. Do not replace follow-up imaging with blood tests. Tumour markers are not an early-detection tool — see the review of CA 15-3.
6. Keep previous images and reports. Comparison with a prior study is the strongest evidence that a finding is stable.

All decisions about follow-up, further imaging or treatment are made by a doctor in person, with your images at hand. This page explains a record in a document; it does not replace a consultation.

The short version

N60 is the code for benign mammary dysplasia — fibrocystic breast change. It is a common condition, not cancer and not a stage of it; malignant disease has its own category. The code itself describes neither the size nor the structure of a finding: the meaning lies in the report text, the BI-RADS category and the follow-up interval your doctor sets.